Circulating selenoprotein P levels in relation to MRI‐derived body fat volumes, liver fat content, and metabolic disorders

Giuseppe, Romina di; Koch, Manja; Schlesinger, Sabrina; Borggrefe, Jan; Both, Marcus; Müller, Hans‐Peter; Kassubek, Jan; Jacobs, Gunnar; Nöthlings, Ute; Lieb, Wolfgang

doi:10.1002/oby.21841

Cited by 24 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the largest to-date study, liver fat content, evaluated with magnetic resonance imaging, showed a J-shaped association with SEPP, with the highest rates observed in individuals with low SEPP levels [19]. SEPP levels were also shown to be inversely associated with MetS [19,24]. These and our findings are contradictory to other 2 studies showing higher SEPP in NAFLD patients than controls [17,18].…”

Section: Discussioncontrasting

confidence: 99%

“…This trend remained robust after adjustment for potential cofounders, but not for IR. In the largest to-date study, liver fat content, evaluated with magnetic resonance imaging, showed a J-shaped association with SEPP, with the highest rates observed in individuals with low SEPP levels [19]. SEPP levels were also shown to be inversely associated with MetS [19,24].…”

Section: Discussionmentioning

confidence: 95%

“…Existing data for SEPP in NAFLD are limited and conflicting. Some authors reported higher SEPP in NAFLD patients than controls [17,18], whereas others a J-shaped relation of SEPP with hepatic steatosis [19].…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease

Polyzos

Mavrouli

Katsinelos

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Objective Main aim of this study was to evaluate circulating selenoprotein P (SEPP) levels in patients with simple steatosis (SS) and nonalcoholic steatohepatitis (NASH) compared with healthy controls. Methods Thirty-one patients with biopsy-proven NAFLD (15 with SS, 10 with borderline NASH, 6 with definite NASH) and 27 matched controls without NAFLD were enrolled. Serum SEPP levels and liver function tests plus biochemical parameters were measured with ELISA and standard methods, respectively. Homeostatic model of assessment - insulin resistance (HOMA-IR) was calculated. Results SEPP levels were statistically different between groups (p-value for trend=0.043). In pairwise comparisons, SEPP was lower in definite NASH compared with controls (p=0.029), but not SS (p=0.18) or borderline NASH (p=0.35). SEPP was not different between controls, SS and borderline NASH. The unadjusted trend between the controls, SS and NASH patients remained essentially unchanged after adjustment for age, sex, log(ALT) and waist circumference, but it marginally lost significance when log(HOMA-IR) entered into the model. SEPP levels were not different between groups of different severity of steatosis, fibrosis, hepatocellular ballooning, lobular and portal inflammation. Conclusions Lower SEPP levels were observed in patients with definite NASH compared with controls, a finding warranting larger studies.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease

Polyzos

Mavrouli

Katsinelos

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…In young children, increased SELENOP concentrations were reported to be negatively associated with certain components of metabolic syndrome, such as waist circumference and blood pressure 11 . A clinical study using magnetic resonance imaging reported negative correlations between serum SELENOP and visceral and subcutaneous fat volumes 12 . In contrast, another study found the opposite pattern, where plasma SELENOP was increased in people with obesity, but was not independently associated with the severity of insulin resistance 13 .…”

Section: Introductionmentioning

confidence: 99%

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population

Makino

Saito

et al. 2018

Sci Rep

View full text Add to dashboard Cite

We aimed to test the hypothesis that selenoprotein P (SELENOP), a hepatokine involved in the development of both insulin resistance and impaired insulin production in mice, is related to future onset of hyperglycemia in humans. 76 healthy non-pregnant human subjects without diabetes underwent oral glucose tolerance test (OGTT) at baseline and 4-years follow-up. Nine subjects developed either impaired glucose tolerance or type 2 diabetes at follow-up. At baseline, SELENOP concentrations correlated negatively with insulinogenic index, but not with homeostasis model assessment-estimated insulin resistance (HOMA-IR). Multivariate analysis showed that baseline SELENOP predicted fasting plasma glucose at follow-up independently of the other parameters. The receiver operating characteristic (ROC) curve analysis showed that baseline concentrations of serum SELENOP, but not of selenium, were a reliable test to predict future onset of glucose intolerance. In conclusion, elevation of circulating SELENOP, but not of circulating selenium, was positively and independently associated with future onset of glucose intolerance in a general Japanese population.

show abstract

“…Other Diseases Several reports have indicated positive correlations between high plasma SeP levels and obesity and/or metabolic syndromes, as well as nonalcoholic fatty liver disease, 58,[61][62][63] although this is still controversial, as others have reported an inverse correlation. 59,64,65) Of note, however, these results were derived from using not necessarily the same method, suggesting the need for standardization of SeP quantification. Further efforts are needed to clarify the entire relationship between plasma SeP level and metabolism, as proposed previously.…”

Section: Pah and Sepmentioning

confidence: 99%

Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More

Tsutsumi

Saito

2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Selenoprotein P (SeP) is one of the 25 human selenocysteine (Sec)-containing proteins, and is generally thought to function as a plasma carrier of the trace element selenium in the body. Recent studies, however, indicate unsuspected pivotal roles of SeP in human diseases, particularly in type 2 diabetes mellitus (T2DM) and pulmonary arterial hypertension (PAH). In this review, we will summarize the characteristics of SeP and recent advances in the field, especially focusing on the emerging roles of SeP in pathophysiological conditions. We will also discuss potential medical/pharmaceutical applications targeting SeP.

show abstract

Circulating selenoprotein P levels in relation to MRI‐derived body fat volumes, liver fat content, and metabolic disorders

Abstract: The findings suggest inverse associations of circulating SELENOP concentrations with several metabolic traits, to be further investigated in longitudinal studies.

Cited by 24 publications

References 38 publications

Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease

Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease

Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population

Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More

Contact Info

Product

Resources

About